Daiwa Securities Group Inc. Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN)

Daiwa Securities Group Inc. acquired a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 43,097 shares of the company’s stock, valued at approximately $67,000.

Several other large investors also recently added to or reduced their stakes in OCGN. Bank of New York Mellon Corp increased its stake in Ocugen by 2,760.5% during the second quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock worth $1,165,000 after acquiring an additional 725,536 shares during the last quarter. Rhumbline Advisers increased its stake in Ocugen by 3,040.0% during the second quarter. Rhumbline Advisers now owns 301,218 shares of the company’s stock worth $467,000 after acquiring an additional 291,625 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Ocugen during the first quarter valued at approximately $132,000. Tidal Investments LLC bought a new position in shares of Ocugen during the first quarter valued at approximately $108,000. Finally, Headlands Technologies LLC bought a new position in shares of Ocugen during the first quarter valued at approximately $66,000. 10.27% of the stock is owned by institutional investors.

Ocugen Trading Down 4.3 %

OCGN opened at $1.12 on Wednesday. The stock has a market cap of $288.24 million, a price-to-earnings ratio of -4.48 and a beta of 3.69. The stock’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.46. Ocugen, Inc. has a one year low of $0.35 and a one year high of $2.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.04 and a current ratio of 1.04.

Ocugen (NASDAQ:OCGN) last released its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $1.14 million for the quarter. During the same quarter last year, the company posted ($0.10) earnings per share. On average, equities analysts forecast that Ocugen, Inc. will post -0.2 EPS for the current year.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.